Plenary Session

By Vinay Prasad, MD MPH

Listen to a podcast, please open Podcast Republic app. Available on Google Play Store.


Category: Science & Medicine

Open in Apple Podcasts


Open RSS feed


Open Website


Rate for this podcast

Subscribers: 71
Reviews: 1


 Feb 5, 2020

Description

A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Episode Date
3.12 TMPRSS2, Cancer Imaging with Drs. Becker and Woo, Clinical Epidemiology with Dr. Thomas Newman
02:35:41
We start this week's episode by critically examining the new paper titled "Racial/Ethnic Variation in Nasal Gene Expression of Transmembrane Serine Protease 2 (TMPRSS2)" and asking, is it racist? After that, we discuss advances in prostate cancer imaging with two imaging specialists from Memorial Sloan Kettering Cancer Center, Drs. Anton Becker and Sungmin Woo. Finally, we have a far-reaching interview with Dr. Thomas Newman of University of California San Francisco on clinical epidemiology and his new book Evidence-Based Diagnosis: An Introduction to Clinical Epidemiology. TMPRSS2 and COVID-19: doi.org/10.1001/jama.2020.17386 PSMA PET-CT: doi.org/10.1016/S0140-6736(20)30314-7 Evidence-Based Diagnosis: https://www.cambridge.org/core/books/evidencebased-diagnosis/2807345CA679EC723697ED9C6D98A1AA Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Sep 19, 2020
3.11 Experts, Lockdown, Affirmative Action, & COVID-19 and Hearts with Professor Darrel Francis
02:00:44
This week's monologue touches on the credibility of expert speakers, evaluating the COVID-19 lockdown as health policy, and the anti-affirmative action white paper written by Dr. Norman Wang and its controversy. In the second half of the episode we interview Professor Darrel Francis of Imperial College London on COVID-19 cardiology and Vascepa. Anti-Affirmative Action: doi.org/10.1161/JAHA.120.015959 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Sep 12, 2020
3.10 Colon Cancer Screening, Vascepa Patent with Jonathan Darrow, PREVENTT with Dr. Toby Richards
02:02:26
We have a number of topics for you this week! Among them, we cover the issue of colon cancer screening, especially in the light of Chadwick Boseman's recent passing. We interview Jonathan Darrow, an Assistant Professor at Harvard Medical School and faculty at Brigham and Women's Hospital, on patent litigation and the recent patent appeal for Vascepa. Finally, we interview Dr. Toby Richards, Professor of Surgery, on running clinical trials and, specifically, the results of his recent trial PREVENTT, out now in The Lancet. PREVENTT: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31539-7/fulltext Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Sep 05, 2020
3.09 COVID-19 Risk, Financial Toxicity, & HALT-IT for Journal Club with Fellow Dr. Justine Ryu
01:24:05
We start this week's episode by revisiting our discussion from last week on the PNAS study on racial concordance and birthing mortality. We continue our theme of critical appraisal by then tearing apart the recent paper published in BMJ titled "Two metres or one: what is the evidence for physical distancing in covid-19?" and its inability to support its colorful figures. We end the monologue with a few thoughts on academics who somehow author one paper a week. Finally, we turn to the last two segments of the show: the first is a discussion with Dr. Bishal Gyawali on his new paper out now in The Lancet Haematology titled "A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries" and the second is Journal Club with a Fellow, where we interview Dr. Justine Ryu on a paper published in The Lancet titled "Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial". Racial Concordance: doi.org/10.1073/pnas.1913405117 COVID-19 Risk: doi.org/10.1136/bmj.m3223 Financial Toxicity: doi.org/10.1016/S2352-3026(20)30258-1 HALT-IT: doi.org/10.1016/S0140-6736(20)30848-5 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Aug 29, 2020
3.08 Racial Concordance in Birthing Mortality & HERO for Journal Club with Fellow Dr. Michael Burns
01:33:09
This week we take a deep dive into two recently published studies, their surrounding controversy, and the broader implications. The first study was published in the journal Proceedings of the National Academy of Sciences of the USA and is titled "Physician–patient racial concordance and disparities in birthing mortality for newborns". The second was published in the New England Journal of Medicine and is titled "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer", commonly known as the HERO trial. We discuss the HERO trial with Dr. Michael Burns of Northwestern as part of our new segment, Journal Club with a Fellow. Racial Concordance: doi.org/10.1073/pnas.1913405117 HERO: doi.org/10.1056/NEJMoa2004325 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Aug 22, 2020
3.07 Lung Cancer Omics and Mortality, PPIs and COVID-19, & RECIST with Dr. Elizabeth Eisenhauer
02:42:03
We have a lot in store for you this week! We start off by evaluating two recently published studies: "Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer" (published in the Journal of Clinical Oncology: Oncology Practice) and "The Effect of Advances in Lung-Cancer Treatment on Population Mortality" (published in the New England Journal of Medicine). We talk a bit about tracking down the validity of a reference. We sit down with Dr. Branden Tarlow to discuss his thoughts on PPIs and COVID-19 acquisition. Finally, we conclude the episode by interviewing Dr. Elizabeth Eisenhauer of Queen's University in Kingston, Ontario, Canada on her career in cancer medicine. Omics-Based Strategies: doi.org/10.1200/OP.20.00117 Population Mortality: doi.org/10.1056/NEJMoa1916623 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Aug 15, 2020
3.06 COVID-19 Vaccine Access, ADAURA, QOTW, & Journal Club with Fellow Dr. Karine Tawagi
01:55:39
We start this week's episode by discussing access to investigational COVID-19 vaccines and recapping the problems with the ADAURA study. We transition from there to a Question of the Week with medical student Audrey Tran of Oregon Health & Science University. Finally, we introduce a new segment - Journal Club with a Fellow. In this inaugural segment we invite Dr. Karine Tawagi of the Oschner Clinic in Louisiana to the podcast to talk about IMbrave150. IMbrave150: doi.org/10.1056/NEJMoa1915745 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Aug 07, 2020
3.05 LIVE! A Midsummer Night's Stream
01:16:10
This is the recording of a LIVE episode of Plenary Session in which Dr. Sue S Yom interviewed our host, Dr. Vinay Prasad, on how he built his career and how he conceptualizes his work. There's also a surprise guest near the end! Thank you to Dr. Kaleigh Doke, Dr. Brian Kavanagh, and the Virtual Visiting Professor Network for hosting this special episode. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Jul 30, 2020
3.04 Listener Questions & MedTwitter and Risk-Benefit Profile of Ramucirumab with Dr. Bishal Gyawali
01:31:46
This week we respond to several questions sent in by listeners and then we interview Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada on MedTwitter, other recent events, and his recently published paper titled "Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials". Ramucirumab: doi.org/10.1016/j.eclinm.2020.100458 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Jul 24, 2020
3.03 The National Lung Matrix Trial & the Major Flaw of the SPRINT Trial with Dr. Mark Friedberg
01:09:28
This week we discuss two major papers: The first was just recently released in Nature and it's titled "The National Lung Matrix Trial of personalized therapy in lung cancer". The second is a few years old, but exemplifies the importance of trial design. We discuss the second paper, titled "A Randomized Trial of Intensive versus Standard Blood-Pressure Control" and published in the New England Journal of Medicine with Dr. Mark Friedberg, a health policies and performance measurement researcher. National Lung Matrix Trial: doi.org/10.1038/s41586-020-2481-8 SPRINT: doi.org/10.1056/NEJMoa1511939 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Jul 18, 2020
3.02 BONUS! National Clinician Scholars Program with Dr. Hilary Seligman
00:34:26
This week's BONUS episode is a discussion of the National Clinician Scholars Program with Dr. Hilary Seligman, the head of the program at University of California, San Francisco. The deadline for the application for the 2021-2023 cohort is July 15, 2020 (very soon!), though there may be some leniency due to the pandemic. National Clinician Scholars Program: https://nationalcsp.org/ UCSF National Clinician Scholars Program: https://nationalscholars.ucsf.edu/ Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Jul 13, 2020
3.01 Risk of COVID-19 Among Users of PPIs, Time to Treatment Initiation, & Dr. Lynora Saxinger
01:41:44
This week we discuss recent research (and the accompanying Twitter thread) on the risk of COVID-19 among users of proton pump inhibitors (PPIs). We also hold a philosophical discussion on the research surrounding time to treatment initiation (TTI) in cancer medicine. We end the episode with an interview with Dr. Lynora Saxinger of the University of Alberta, Edmonton, a specialist in Infectious Diseases. PPIs and risk of COVID-19: https://twitter.com/BrennanSpiegel/status/1280527527325265920 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Jul 11, 2020
2.60 BONUS! Cancer Meta-Research 101: The Lay of the Land of Cancer Research
00:52:33
This BONUS episode is the recording of a lecture given on June 18, 2020 as part of Stanford's METRICS International Forum. METRICS stands for Meta-Research Innovation Center at Stanford University. This lecture is geared towards a broad audience and aims to provide a general sense of current cancer research. The lecture is titled "Cancer Meta-Research 101". Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Jul 07, 2020
2.59 The Best Doctor, Selinexor, & Annotation Services for NGS with Drs. Katsoulakis and Kelley
01:15:28
This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology. Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal of Clinical Oncology: Precision Oncology, titled "Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program". Selinexor: doi.org/10.1016/S2352-3026(20)30120-4 Annotation Services: doi.org/10.1200/PO.19.00118 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
Jul 03, 2020
2.58 RECOVERY & Twitter, Academic Debate, and Transitioning Your Career with Dr. Andrae Vandross
01:21:03
This week we briefly cover updates on the RECOVERY trial before segueing into an interview with Dr. Andrae Vandross on Twitter (specifically #medtwitter), academic discussions, and changing your career to find your calling. RECOVERY: www.recoverytrial.net/ Malignant audiobook: www.audible.com/pd/B08864KFHW/?so…ACX0_195112_rh_us Back us on Patreon! www.patreon.com/plenarysession
Jun 27, 2020
2.57 RECOVERY, Clinical Trials in the US, EFS, Writing, Dr. Raj Chetty, & Dr. Ian Tannock
02:14:41
This week's episode is jam-packed with topics! We talk about the RECOVERY trial, the U.S. clinical trial infrastructure, event-free survival (EFS) and cost of care in acute myeloid leukemia, how long it takes to write papers in academic medicine, threats to public health officials, and the application to medicine of Dr. Raj Chetty's work in economics. Finally, we interview this week's special guest, Dr. Ian Tannock, on docetaxel, prostrate cancer, clinical trial appraisal, and his career in medicine. RECOVERY: https://www.recoverytrial.net/ EFS in AML: doi.org/10.1182/bloodadvances.2019001150 Malignant audiobook: https://www.audible.com/pd/B08864KFHW/?source_code=AUDFPWS0223189MWT-BK-ACX0-195112&ref=acx_bty_BK_ACX0_195112_rh_us Back us on Patreon! www.patreon.com/plenarysession
Jun 19, 2020
2.56 HER2CLIMB & Misinformation and Disinformation with Dr. Cailin O'Connor
01:02:24
This week we tackle the topic of tucatinib in HER2-positive breast cancer with brain metastases. We also interview Dr. Cailin O'Connor of the University of California Irvine on her research on misinformation and disinformation. We discuss her recent article in the Boston Review, titled "Hydroxychloroquine and the Political Polarization of Science", as well as her extensive body of work. HER2CLIMB: doi.org/10.1200/JCO.20.00775 Hydroxychloroquine: http://bostonreview.net/science-nature-politics/cailin-oconnor-james-owen-weatherall-hydroxychloroquine-and-political The Dynamics of Retraction in Epistemic Networks: http://philsci-archive.pitt.edu/17088/ How Misinformation Spreads: https://www.scientificamerican.com/article/how-misinformation-spreads-and-why-we-trust-it/ Back us on Patreon! www.patreon.com/plenarysession
Jun 12, 2020
2.55 Hydroxychloroquine for COVID-19, ASCO, QOTW, Private Equity in Medicine with Dr. Jane Zhu
02:06:33
We start this week's episode by covering some recent research: After thoroughly critiquing the recent randomized trial of hydroxychloroquine for postexposure prophylaxis for COVID-19, we then discuss the five abstracts selected for plenary sessions at the recent virtual meeting of the American Society of Clinical Oncology. We transition from there to a Question from a Medical Student with Audrey Tran of Oregon Health & Science University on the recent decision to make the USMLE Step 1 exam pass/fail. Finally, we end with an interview with Dr. Jane Zhu, also of OHSU, on her current research and her new paper published in JAMA titled, "Private Equity Acquisitions of Physician Medical Groups Across Specialties, 2013-2016". Dr. Zhu first guest-starred on Plenary Session in episode 1.31. Hydroxychloroquine: doi.org/10.1056/NEJMoa2016638 JAVELIN: https://meetinglibrary.asco.org/record/186872/abstract ECOG-ACRIN: https://meetinglibrary.asco.org/record/186884/abstract ENDURANCE: https://meetinglibrary.asco.org/record/186906/abstract KEYNOTE-177: https://meetinglibrary.asco.org/record/186928/abstract ADAURA: https://meetinglibrary.asco.org/record/191929/abstract Private Equity Acquisitions: doi.org/10.1001/jama.2019.21844 Listen to the audiobook of Malignant with a free 30-day trial from Audible! https://www.audible.com/pd/B08864KFHW/?source_code=AUDFPWS0223189MWT-BK-ACX0-195112&ref=acx_bty_BK_ACX0_195112_rh_us Back us on Patreon! www.patreon.com/plenarysession
Jun 05, 2020
2.54 Classical Hematology Chat on Thrombosis in COVID-19 & Drugs for COVID-19 with Dr. Walid Gellad
02:07:20
This week we talk all things COVID-19! We start with an in-depth Classical Hematology Chat with Dr. Sven Olson and Dr. Joseph Shatzel of Oregon Health & Science University on thrombosis and anticoagulation in COVID-19, touching on a number of recent studies. We then turn to a conversation with Dr. Walid Gellad of the University of Pittsburgh on new pharmaceutical treatments for COVID-19. Tang et al. paper: doi.org/10.1111/jth.14768 Prospective autopsy study: doi.org/10.7326/M20-2566 COVID-19 compared to H1N1: doi.org/10.1056/NEJMoa2015432 Hypercoagulability of COVID-19: doi.org/10.1111/jth.14850 JACC letter: doi.org/10.1016/j.jacc.2020.05.001 JACC podcast: https://podcasts.apple.com/us/podcast/association-treatment-dose-anticoagulation-in-hospital/id932118437?i=1000474262300 Venous Thromboembolism in COVID-19: doi.org/10.1111/jth.14888 Back us on Patreon! www.patreon.com/plenarysession
May 31, 2020
2.53 Why Agreeing 65% with Someone is Important & COVID-19 Health Policy with Dr. Daniel Morgan
01:04:31
This week we discuss why being open-minded enough to agree partially with someone - instead of taking an all-or-nothing approach to a discourse - is important. We also sit down with epidemiologist Dr. Daniel Morgan of the University of Maryland School of Medicine to critique the public health policy concerning COVID-19 transmission. Back us on Patreon! www.patreon.com/plenarysession
May 23, 2020
2.52 Malignant Audiobook, PROfound trial, & Literature and Medicine with Dr. Adam Cifu
01:43:36
This week we have an announcement -- the audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer", written and narrated by our host Vinay Prasad, is available now on Amazon, iTunes, and Audible! We also have an in-depth journal club for you on the findings of the PROfound trial as published in a new paper out in the New England Journal of Medicine titled "Olaparib for Metastatic Castration-Resistant Prostate Cancer". Finally, we end the episode with an interview with Dr. Adam Cifu of the University of Chicago on literature, medicine, maintaining a feeling of normalcy and self during COVID-19, and more! Listen to Malignant with a free 30-day trial of Audible: https://www.audible.com/pd/B08864KFHW/?source_code=AUDFPWS0223189MWT-BK-ACX0-195112&ref=acx_bty_BK_ACX0_195112_rh_us PROfound: doi.org/10.1056/NEJMoa1911440 Crossover: doi.org/10.1093/annonc/mdy116 Back us on Patreon! www.patreon.com/plenarysession
May 16, 2020
2.51 BONUS! Clinical Trials Part 3
01:00:58
This BONUS lecture was a talk given to the Hematology/Oncology fellows at Oregon Health & Science University. It's part three of a three-part series on clinical trials. Back us on Patreon! www.patreon.com/plenarysession
May 13, 2020
2.50 Neil Ferguson, Ending Lockdown, & Updates on COVID-19 Management with Dr. Benjamin Singer
01:06:40
This week's topic is all things COVID-19 -- we discuss the viral scandal of British epidemiologist Neil Ferguson's actions and how it reflects (or doesn't) on his work, we talk about the nuances of how to end lockdowns, and we bring back Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University, to address updates in the ICU management of COVID-19. Invisible Pandemic: doi.org/10.1016/S0140-6736(20)31035-7 Back us on Patreon! www.patreon.com/plenarysession
May 07, 2020
2.49 COVID-19 Contrarians, Remdesivir, & Book Club on "Malignant" with OHSU HemOnc Fellows
01:26:05
This week we begin with a monologue on the recent controversy surrounding Dr. John Ioannidis's published opinions on the COVID-19 pandemic. We end with a group discussion with Oregon Health & Science University's Hematology/Oncology fellows on our host's, Vinay Prasad's, new book "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer." Expressing different views on COVID-19: https://www.statnews.com/2020/04/27/hear-scientists-different-views-covid-19-dont-attack-them/ Malignant: www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
May 02, 2020
2.48 BONUS! Introduction to Malignant: How Bad Policy and Bad Evidence Harm People with Cancer
00:20:31
This week we have a BONUS episode for you! As a teaser to the forthcoming audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer" by Dr. Vinay Prasad (our host), Audrey Tran and Ian Straehley have set the introduction of the book to music they composed and arranged themselves. You can buy the print version of Malignant from Amazon: https://www.amazon.com/Malignant-Policy-Evidence-People-Cancer-dp-1421437635/dp/1421437635/ Back us on Patreon! www.patreon.com/plenarysession
Apr 25, 2020
2.47 Remdesivir, Cloth Masks, & Incentives for COVID-19 Drug Development with Dr. Ameet Sarpatwari
01:16:25
This week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice for the general public to wear cloth masks. We end with an interview with Dr. Ameet Sarpatwari of Harvard Medical School on how to create a more effective pharmaceutical system, the CREATES Act of 2019, developing fair and equitable drugs to treat COVID-19, and how to create a just system that balances the need for innovation with the need for access. Dr. Ameet Sarpatwari is the Assistant Director of PORTAL. Compassionate Use of Remdesivir: doi.org/10.1056/NEJMoa2007016 U.S. Gene Therapy Trials: doi.org/10.1001/jama.2019.22214 NIH Fair Pricing Condition: doi.org/10.7326/M19-2576 Back us on Patreon! www.patreon.com/plenarysession
Apr 16, 2020
2.46 Psychology Unearthed by COVID-19 Precautions & Polygenic Risk Score with Dr. Venk Murthy
01:32:41
This week we have a far-reaching monologue on COVID-19 and how people are reacting to the public health recommendations concerning COVID-19 (such as cancelling conferences and school, maintaining 6+ feet of distance, wearing cloth masks). We end with an insightful interview with Dr. Venk Murthy on polygenic risk score and, at the end, a bit about how the world of science is failing to combat hype. Back us on Patreon! www.patreon.com/plenarysession
Apr 11, 2020
2.45 Viral Spread of SARS-CoV-2, Rationing Resources, "Evidence Fiasco", & Classical Hematology Chat
01:26:49
This week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with viruses, Dr. Ezekiel Emanuel's essay on how to fairly allocate dwindling medical resources during this global pandemic, and Dr. John Ioannidis's article on the "evidence fiasco" that has been our response to COVID-19. We end the episode with a Classical Hematology Chat with Drs. Sven Olson and Joseph Shatzel. Dr. Mukherjee's article: https://www.newyorker.com/magazine/2020/04/06/how-does-the-coronavirus-behave-inside-a-patient Allocation of Medical Resources: doi.org/10.1056/NEJMsb2005114 Dr. Ioannidis's article: https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/ Back us on Patreon! www.patreon.com/plenarysession
Apr 01, 2020
2.44 ICU Management of COVID-19 with Dr. Benjamin Singer
00:37:57
This week we discuss management of COVID-19 in the intensive care unit with Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University. We discuss medications, PPE, ventilators, and more! Back us on Patreon! www.patreon.com/plenarysession
Mar 25, 2020
2.43 BONUS! Novel Coronavirus and the COVID-19 Response in Oregon with Dr. John Townes
00:41:59
This bonus episode is an interview from March 16, 2020 with Dr. John Townes, the Interim Head for the Division of Infectious Disease and the Medical Director for Infection Prevention and Control here at Oregon Health & Science University. We talk about the novel coronavirus and how healthcare professionals are responding to the COVID-19 pandemic, with a focus on Oregon. Back us on Patreon! www.patreon.com/plenarysession
Mar 18, 2020
2.42 Quality-of-Life Measurement in Oncology, KnowYourTumor, & Question of the Week
01:08:25
This week we discuss two recent papers -- one we praise, one we condemn -- and then we turn to a question of the week with medical student Audrey Tran on self-improvement and "refining conviction". The first paper is titled "Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials" and the second is titled "Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial". Quality of Life Measurement: doi.org/10.1001/jamanetworkopen.2020.0363 KnowYourTumor: doi.org/10.1016/S1470-2045(20)30074-7 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
Mar 17, 2020
2.41 BONUS! Clinical Trials Part 2: Crossover and Control Arms
00:51:40
This BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part two of a three-part series on clinical trials. This talk is on clinical trial design, specifically crossover and control arms. Back us on Patreon! www.patreon.com/plenarysession
Mar 11, 2020
2.40 BEACON part 2, NALA, & Molecular Pathology and Next-Generation Sequencing with Dr. David Carr
01:09:11
This week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our thoughts on what they said. We then turn to the FDA's recent approval of neratinib in combination with capecitabine for HER2-positive breast cancer, based on the phase III NALA trial. Finally, we interview Dr. David Carr, a Molecular Pathology Fellow at UC San Diego, on his work in general and, specifically, next-generation sequencing. BEACON Letters to the Editor: www.nejm.org/doi/full/10.1056/NEJMoa1908075#article_letters NALA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
Mar 05, 2020
2.39 Effectiveness of Newer-Generation Antidepressants with Dr. Michael Hengartner
00:42:40
Our guest this week is Dr. Michael Hengartner of the Zurich University of Applied Sciences. We interview him on his work studying the long-term consequences and effectiveness of newer-generation antidepressants - specifically focusing on selective serotonin reuptake inhibitors (SSRIs). Back us on Patreon! www.patreon.com/plenarysession
Feb 27, 2020
2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali
00:51:48
We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem from the drive to disseminate information, not from the drive to advance your own career. We end the episode with an interview with Dr. Bishal Gyawali of Queen's University in Kingston, Canada on his recent paper out in Nature Cancer on global oncology. Specifically, Dr. Gyawali addresses the need for conducting cancer clinical trials in low- and middle-income countries. KEYNOTE-048: doi.org/10.1016/S0140-6736(19)32591-7 Opportunities for Cancer Clinical Trials in LMIC: doi.org/10.1038/s43018-020-0030-x Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
Feb 19, 2020
2.37 Careerism, Presenting Abstracts, Twitter and the K-Index, & Classical Hematology Chat
01:09:48
We have a full slate for you this week! We discuss careerism in medicine, presenting abstracts at conferences, #MedTwitter, and Dr. Califf's opinions on the K-Index. We conclude the episode with our first-ever Classical Hematology Chat, featuring our host Dr. Vinay Prasad, Dr. Sven Olson, and Dr. Joseph Shatzel. The chat is on sickle cell disease. "A Perspective on the K-Index": doi.org/10.1016/j.jaccas.2020.01.003 Back us on Patreon! www.patreon.com/plenarysession
Feb 14, 2020
2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein
00:59:11
This week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein, a hematology/oncology fellow at Vanderbilt University Medical Center, on his new paper published in JAMA Network Open titled "Indication of Measures of Uncertainty for Statistical Significance in Abstracts of Published Oncology Trials: A Systematic Review and Meta-analysis". NELSON: doi.org/10.1056/NEJMoa1911793 Measures of Uncertainty: doi.org/10.1001/jamanetworkopen.2019.17530 Back us on Patreon! www.patreon.com/plenarysession
Feb 07, 2020
2.35 BONUS! How to Keep Up with the New Information in Medicine
01:00:17
This BONUS episode is the recording of a lecture given to medical students titled "How to Keep Up with the New Information in Medicine." It's a primer on the steps healthcare professionals need to take in order to keep abreast of the latest medical findings. Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
Jan 31, 2020
2.34 Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & TAILORx with Dr. Ali Khaki
01:32:10
We have a variety of topics for you this week! We tackle red light therapy, polatuzumab olatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma; we have a hematology/oncology question of the week from Dr. Emerson Chen of OHSU; and we sit down with Dr. Ali Khaki of the Fred Hutchinson Cancer Research Center to discuss his recent paper critiquing TAILORx. Pola for DLBCL: doi.org/10.1200/JCO.19.00172 Financial COI on Twitter: doi.org/10.1001/jamainternmed.2016.8467 Ignoring Valuable Data: doi.org/10.6004/jnccn.2019.7363 Back us on Patreon! www.patreon.com/plenarysession
Jan 24, 2020
2.33 Olaparib and POLO & the Classical Fallacies of Cancer Screening with Dr. H Gilbert Welch
01:13:53
This week we're treating you to a recording of the Grand Rounds lecture on overdiagnosis and cancer screening that Dr. H Gilbert Welch gave at Oregon Health & Science University on October 30, 2019. Before the lecture, we take a moment to reiterate with renewed vigor our distaste for the POLO trial (first discussed in episode 1.64). POLO: doi.org/10.1056/NEJMoa1903387 Back us on Patreon! www.patreon.com/plenarysession
Jan 15, 2020
2.32 BONUS! Clinical Trials Part 1: Thinking Better About Cancer Medicine
00:53:10
This BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part one of a three-part series on clinical trials, titled "Thinking Better About Cancer Medicine". Back us on Patreon! www.patreon.com/plenarysession
Jan 10, 2020
2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali
00:40:09
This week we answer a few questions: the first is from Patreon backer, Harry Hong, on Kaplan-Meier curves. The second is from a student at Mount Sinai Medical School who reached out with some ethical questions they had after the ASH annual meeting on the obligations and responsibilities of peer reviewers. Finally, we end the episode with an interview with Dr. Bishal Gyawali of Queens University in Kingston, Ontario, Canada on his new paper out today in the Journal of the National Comprehensive Cancer Network titled "Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials". Durations of Response: doi.org/10.6004/jnccn.2019.7345 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
Jan 07, 2020
2.30 Questions from a Medical Student & Epidemiology with Dr. Ellie Murray
01:47:54
This week we return to our discussion of going after soft targets vs hard targets, but this time with a focus on how it applies to building a burgeoning career in medicine, in our segment Questions from a Medical Student with Audrey Tran. We end this week's episode with a far-reaching interview with Dr. Ellie Murray (most people know her as Epi Ellie on Twitter and as the co-host of the podcast Casual Inference) on all things epidemiology. Check out Dr. Murray's excellent podcast here: https://casualinfer.libsyn.com/ Back us on Patreon! www.patreon.com/plenarysession
Jan 03, 2020
2.29 Time from Diagnosis to Treatment in AML and Real-World Data with Dr. Sherrie Aspinall
01:09:02
This week we wonder incredulously how this abstract from ASH titled "Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukemia" was selected as one of the top abstracts from the conference. In the second half of the episode we interview Dr. Sherrie Aspinall of the Veterans Administration on how to use real-world data. Her new paper is titled "Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration". Time from diagnosis to treatment in AML: https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2019-123717 Targeted therapies for advanced RCC: doi.org/10.1002/cam4.2531 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
Dec 27, 2019
2.28 Trastuzumab in Later Lines of Therapy for HER2+ Breast Cancer, Kaplan-Meier Curves, & Patreon
01:03:52
We're back in Plenary Session HQ! We have multiple topics for you this week. We cover the use of trastuzumab in later lines of therapy for HER2+ metastatic breast cancer, we take a listener question on Kaplan-Meier curves, and we talk a little about Patreon. Malignant: www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession
Dec 20, 2019
2.27 BONUS! Use of Bone-Modifying Agents Among Medicare Beneficiaries with MM with Dr. Arjun Gupta
00:26:04
This BONUS episode is an interview with Dr. Arjun Gupta, a second-year hem/onc fellow at Johns Hopkins University, on his new paper out TODAY in JAMA Oncology titled ''Use of Bone-modifying Agents among Medicare Beneficiaries with Multiple Myeloma''. Use of bone-modifying agents: doi.org/10.1001/jamaoncol.2019.5426 Back us on Patreon! www.patreon.com/plenarysession
Dec 12, 2019
2.26 Questions of the Week: Hematology/Oncology, USMLE Step 2 CK, & a bonus Hematology/Oncology
00:40:15
This is the last week of pre-recorded episodes -- we'll be back next week with a fresh, hard-hitting monologue. In the meantime, we have three questions of the week for you. Two are inspired by the hematology/oncology boards and are presented by Dr. Sven Olson. Between the two, we have one from Ian Straehely that's inspired by the USMLE Step 2 CK. Back us on Patreon! www.patreon.com/plenarysession
Dec 09, 2019
2.25 Questions of the Week: Hematology/Oncology, the USMLE Step 2 CK, & One From a Med Student
00:47:27
Our host is still out of town, but don't worry -- we have some questions of the week to tide you over. The first is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; the second is inspired by the USMLE Step 2 CK, presented by Ian Straehley; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession
Dec 02, 2019
2.24 Questions of the Week: the USMLE Step 2 CK, Hematology/Oncology, & One From a Med Student
00:37:50
This week our host is still in Australia, but we have some questions of the week saved for you! The first is inspired by the USMLE Step 2 CK, presented by Ian Straehley; the second is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession
Nov 26, 2019
2.23 Question of the Week & Ethics and Inefficiencies of Clinical Trials with Dr. Jonathan Kimmelman
00:58:22
First up this week is Question of the Week inspired by the Hematology/Oncology boards, with Dr. Sven Olson. No monologue on current trials this week because our host is still in Australia, so we conclude the episode with an interview with Dr. Jonathan Kimmelman of McGill University on his extensive work in research ethics, studying the most important issue in cancer medicine today: the risk-benefit of clinical trials and how best to spare patients from the burdens of creating a new drug. Review of Sunitinib: doi.org/10.1093/jnci/djv292 Benefit, Burden, and Impact: doi.org/10.1177/1740774519873883 Back us on Patreon! www.patreon.com/plenarysession
Nov 20, 2019
2.22 Question of the Week & EMR, Talking to Patients, and Being a Doctor with Dr. Robert Hirschtick
00:56:02
This week we have a question of the week from Ian Straehley, inspired by the USMLE Step 2 CK, as well as an interview with Dr. Robert Hirschtick of Northwestern University on what it means to be a doctor, how you should think as a physician, and his many popular pieces published in journals like JAMA. "Copy-and-Paste": doi.org/10.1001/jama.295.20.2335 "Extremities": doi.org/10.1001/jama.300.10.1125 "The Quick Physical Exam": doi.org/10.1001/jama.2016.8182 Robiewon on YouTube: www.youtube.com/channel/UC2Ki7Zbo2VCGQAYinsJhU3w "You Did Not Teach Me What You Thought You Did": doi.org/10.1001/jama.2019.15849 Back us on Patreon! www.patreon.com/plenarysession
Nov 15, 2019
2.21 Aiming for the Hard Targets & Harm From Screening and Overdiagnosis with Dr. H Gilbert Welch
02:13:31
We begin this week's episode by addressing a listener's feedback to our discussion of smoldering multiple myeloma. We then expand on our critique of 'going after the soft targets' (criticizing studies that fall apart with little resistance) by elucidating how to identify and go after hard targets and why it's so important that you do. Finally, we launch into an interview with Dr. H Gilbert Welch that explores his tremendous body of work on the preventable harm that comes from too generous a hand with novel diagnostic advances. Back us on Patreon! www.patreon.com/plenarysession
Nov 08, 2019
2.20 "Courageous Skeptics", Lenalidomide, QOTW, and a Political Conversation with Dr. Andy Saultz
02:35:44
We begin this week's episode with a thoughtful discussion of the internet's "courageous skeptics". Then, after lamenting the way in which the recent study "Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma" was conducted, we end with an interview with Dr. Andy Saultz on his ongoing campaign for Oregon state representative. We break up the interview with a couple Hem/Onc boards questions of the week from Dr. Emerson Chen. Lenalidomide in Smoldering Multiple Myeloma: doi.org/10.1200/JCO.19.01740 Back us on Patreon! www.patreon.com/plenarysession
Nov 01, 2019
2.19 Remembering Dr. Bernard Fisher & Self-Diagnosis with Dr. Mark Lewis
02:13:17
This week we give a short monologue on the late Dr. Bernard Fisher's legacy in the field of oncology, and then dive into a far-ranging interview with Dr. Mark Lewis of Intermountain Healthcare on his career, his family, and diagnosing himself with MEN1 syndrome. Dr. Fisher's obituary in the New York Times: https://www.nytimes.com/2019/10/19/science/dr-bernard-fisher-dead.html Back us on Patreon! www.patreon.com/plenarysession
Oct 25, 2019
2.18 Questions of the Week, Talking About Toxicity, ASCO Guidelines Authors' COI with Dr. Eitan Amir
01:17:26
This week we begin with a critique of the recent perspective article in the New England Journal of Medicine, titled "Talking about Toxicity — 'What We’ve Got Here Is a Failure to Communicate'". After that we interview Dr. Eitan Amir on his paper on undisclosed conflicts of interest among authors of ASCO guidelines. Interspersed between segments of the interview, we invite guest Dr. Sven Olson on to offer a correction to a recent Hem/Onc boards question of the week on Lynch Syndrome (original question posed in episode 2.11) and we invite Ian Straehley on for a question of the week inspired by the USMLE Step 2 CK. Talking about toxicity: doi.org/10.1056/NEJMp1908310  COI among authors of ASCO guidelines: doi.org/10.1002/cncr.32408 Transparency in medicine: doi.org/10.1002/cncr.32407 Back us on Patreon! www.patreon.com/plenarysession
Oct 18, 2019
2.17 Questions of the Week, BEACON, & Use of Subacuate Rehab with Dr. Jonathan Yeh
01:21:53
We start this week's episode with a quick breakdown of why the recent BEACON trial is "the worst trial" host VP has ever read. After that, we have two questions of the week: one from medical student Audrey Tran, and one inspired by the Hem/Onc boards from Dr. Sven Olson. We end with an interview with Dr. Jonathan Yeh of Johns Hopkins University School of Medicine on his recent paper: "Has There Been a Shift in Use of Subacute Rehabilitation Instead of Hospice Referral Since Immunotherapy Has Become Available?". BEACON: doi.org/10.1056/NEJMoa1908075 Subacute Rehabilitation: doi.org/10.1200/JOP.19.00044 Back us on Patreon! www.patreon.com/plenarysession
Oct 08, 2019
2.16 FLAURA & What Truly Matters in the Career of an Academic Physician with Dr. Vinay Prasad
01:37:57
This week we break down the limitations of the recent FLAURA trial and then we're back in the Plenary Session Mobile Command Unit! We have a special guest host, Dr. Christopher Booth of Queen's University in Kingston, Ontario, Canada. He and Dr. Bishal Gyawali, also of Queen's University, conduct a reverse interview with our usual host, Dr. Vinay Prasad of Oregon Health & Science University, on his career, the formation of Plenary Session, and what truly matters in the career of an academic physician. FLAURA: doi.org/10.1056/NEJMoa1713137 Price of an Anticancer Drug: doi.org/10.1001/jamainternmed.2017.3601 Simply Measurable or Clinically Meaningful? doi.org/10.1200/jco.2011.38.7571 The Emperor Has No Clothes: doi.org/10.1200/JCO.2008.19.5594 Making Room in Oncology: www.medscape.com/viewarticle/917628 Back us on Patreon! www.patreon.com/plenarysession
Oct 02, 2019
2.15 Bonus! The Value of Progression-Free Survival as a Treatment Endpoint with Dr. Michael Raphael
00:35:27
This BONUS episode is an interview with Dr. Michael Raphael of Sunnybrook Health Sciences Centre in Toronto, Ontario on his new paper out today in JAMA Oncology: "The value of progression-free survival as a treatment endpoint among patients with advanced cancer: a systematic review and qualitative assessment of the literature". Value of PFS: https://jamanetwork.com/journals/jamaoncology/article-abstract/2751879 Back us on Patreon! www.patreon.com/plenarysession
Sep 26, 2019
2.14 Questions of the Week & Qualifications of a Fellowship Applicant with Dr. Jeremy Cetnar
01:41:06
This week we sit down with Dr. Jeremy Cetnar, director of the Oregon Health & Science University Hematology & Oncology Fellowship Program. In this far-ranging interview, we discuss what he is looking for when reviewing applications to the fellowship program. We also have two questions of the week: one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology. Tweetorials: http://doi.org/10.1056/NEJMp1906790 Back us on Patreon! www.patreon.com/plenarysession
Sep 24, 2019
2.13 BONUS! RCTs Supporting Approvals of Cancer Drugs by EMA with Dr. Huseyin Naci
00:39:32
On this week's BONUS episode, we sit down with Dr. Huseyin Naci, Assistant Professor of Health Policy at the London School of Economics, to discuss his new paper that came out Wednesday (producer's edit: not "yesterday" as said in the podcast - apologies for the delay!) in the British Medical Journal. The paper's titled "Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis." RCTS Supporting Approvals: doi.org/10.1136/bmj.l5221 Back us on Patreon! patreon.com/plenarysession
Sep 20, 2019
2.12 Questions of the Week, Ethics of RCTs, & Transmission and Medical Overuse with Dr. Dan Morgan
01:37:47
We begin this week's episode by revisiting last week's topic on the ethics of randomized controlled trials (RCTs) to address some of the controversy stirred up by our episode. We transition from there to an interview with Dr. Dan Morgan of the University of Maryland School of Medicine on hospital transmission and medical overuse. We have two questions of the week, as well -- one from Ian Straehley, inspired by the USMLE Step 2 CK; and one from Audrey Tran, inspired by the life of a medical student. Back us on Patreon! www.patreon.com/plenarysession
Sep 17, 2019
2.11 Questions of the Week, When RCTs are Necessary, & AYA Oncology with Dr. Adam Duvall
01:41:29
After a hiatus from our segment on reviewing recent trials, we return to discuss the need for randomized controlled trials (RCTs). In the wake of the 2019 World Conference on Lung Cancer, we focus on whether a phase III trial of selpercatinib (LOXO-292) in RET rearranged lung cancer is feasible, practical, and ethical. We also have two questions of the week in this episode -- one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology -- as well as an interview with Dr. Adam Duvall of OHSU on his career in the field of adolescent and young adult (AYA) oncology. Back us on Patreon! patreon.com/plenarysession
Sep 12, 2019
2.10 Questions of the Week: the USMLE Step 2 CK, the MKSAP, & Hematology/Oncology
00:23:27
We have three questions for you this week: one from Ian Straehley, inspired by the USMLE Step 2 CK; one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology. Back us on Patreon! www.patreon.com/plenarysession
Sep 05, 2019
2.09 Questions of the Week & Informed Consent in Clinical Trials with Dr. Lynn Jansen
01:20:18
We start this week with two Questions of the Week: the first is from Ian Straehley on the USMLE Step 2 CK, and the second is from Dr. Sven Olson on hematology/oncology. We end with an interview with Dr. Lynn Jansen of OHSU on the therapeutic misconception, optimism bias, and a deep discussion of the ethics of consenting patients for enrollment in early-phase clinical research trials. Back us on Patreon! www.patreon.com/plenarysession
Aug 28, 2019
2.08 Questions of the Week: the MKSAP, the USMLE Step 2 CK, & From a Med Student
00:37:24
We have three questions for you this week: one from Dr. Derrick Tao, inspired by the MKSAP, the cause for retro-orbital pain; one from Ian Straehley, inspired by the USMLE Step 2 CK, on the test for diagnosing myasthenia gravis; and one from Audrey Tran, inspired by her musings as a medical student and how research can be translated from the lab to the clinic. Back us on Patreon! www.patreon.com/plenarysession
Aug 22, 2019
2.07 Translational Research & Physical Examination Pet Peeves with Dr. Adam Cifu
01:17:12
We start this week's episode with a Question of the Week from medical student Audrey Tran on translational research and medical student training. Afterwards, we have an in-depth interview with Dr. Adam Cifu of the University of Chicago on his recent publication: "Physical Examination Pet Peeves". Pet Peeves: doi.org/10.4300/JGME-D-18-01063.1 Back us on Patreon! www.patreon.com/plenarysession
Aug 16, 2019
2.06 Heart Failure, Choosing a Specialty, & the Bayesian Approach with Dr. Frank Harrell
01:49:30
We're back with more questions of the week! Our first question, from Ian Straehley, is inspired by the USMLE Step 2 CK; our second question, from Audrey Tran, is on deciding on a medical specialty. We end the episode with an interview with Dr. Frank Harrell of Vanderbilt University on the Bayesian approach to statistical thinking. Back us on Patreon! www.patreon.com/plenarysession
Aug 06, 2019
2.05 Reup! Cancer Screening 101 with Dr. Adam Obley
01:12:46
In this REUP episode, we replay a section of our interview with Dr. Adam Obley of OHSU: a primer on cancer screening. This audio was first aired on episode 2.03. Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73 Mammography Screening: Truth, Lies and Controversy: www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853 Back us on Patreon! www.patreon.com/plenarysession
Jul 31, 2019
2.04 Reup! Tumor-Treating Fields for Glioblastoma with Dr. Michael Hayes
00:35:58
In this REUP episode, we replay a section of our interview with Dr. Michael Hayes of Kaiser Permanente. This audio was first aired on episode 2.01. The interview is on the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme. TTF: doi.org/10.1016/j.jcpo.2019.100189 Back us on Patreon! www.patreon.com/plenarysession
Jul 30, 2019
2.03 Dr. Charles Moertel and the Modern Oncologist & Cancer Screening 101 with Dr. Adam Obley
02:05:38
This week we launch a new segment on Plenary Session: Question of the Week! We invite Dr. Sven Olson on to ask a sample hematology/oncology boards question and we invite Audrey Tran on to ask a question from a medical student. Before that, we talk about the legacy of Dr. Charles Moertel and how modern oncologists, in contrast, will be remembered. We end the episode with an interview with Dr. Adam Obley of OHSU -- his fourth appearance on the podcast! -- on cancer screening. Dr. Moertel's obituary: https://www.nytimes.com/1994/06/29/obituaries/charles-moertel-66-studied-treatment-and-cost-of-cancer.html Faith Lost, a Doctor Turns Bitter: https://www.latimes.com/archives/la-xpm-1993-09-12-mn-34516-story.html Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73 Mammography Screening: Truth, Lies and Controversy: https://www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853 Back us on Patreon! www.patreon.com/plenarysession
Jul 23, 2019
2.02 BONUS! Improving Access to Prescription Drugs through Policy Change with Dr. Stacie Dusetzina
00:44:42
This BONUS episode is a recording of a lecture that Dr. Stacie Dusetzina of Vanderbilt University gave for grand rounds at OHSU on June 19, 2019. The lecture is on the cost of prescription drugs and out-of-pocket spending. Back us on Patreon! www.patreon.com/plenarysession
Jul 17, 2019
2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter
02:38:29
Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme; and an interview with Dr. Stacie Dusetzina - a leading researcher in health care policy and the cost of cancer drugs, and an avid Twitter user - of Vanderbilt University on #MedTwitter. ECHELON-2: doi.org/10.1016/S0140-6736(18)32984-2 Facing Our Mistakes: doi.org/10.1056/NEJM198401123100211 Parachutes: doi.org/10.9778/cmajo.20170088 TTF: doi.org/10.1016/j.jcpo.2019.100189 Impact of Disclosing Financial Ties: doi.org/10.1001/archinternmed.2010.39 Back us on Patreon! www.patreon.com/plenarysession
Jul 12, 2019
1.68 Voxeletor with Dr. Olson & Humanizing Cancer, Defining Cancer, and more with Dr. David Steensma
02:05:30
We begin this week's episode by breaking down the recent phase III trial on voxeletor in sickle cell disease with Dr. Sven Olson of OHSU. Next, we feature guest Dr. David Steensma of the Dana-Farber Cancer Institute in a far-reaching interview on being well-read, running a small lab, humanizing cancer, learning from our past use of erythropoiesis-stimulating agents, understanding the headache of contract research organizations, defining cancer, and more! Voxeletor in Sickle Cell: doi.org/10.1056/NEJMoa1903212 Don't Mention It: doi.org/10.1200/JCO.2008.17.7238 The Raven: doi.org/10.1200/JCO.2017.76.3458 Erythropoietin Use in Cancer: doi.org/10.1200/JCO.2005.05.036 Contract Research Organizations: doi.org/10.1002/cncr.29994 Back us on Patreon! www.patreon.com/plenarysession
Jul 05, 2019
1.67 MONALEESA-7 and the Cost of Cancer Drugs with Dr. Stacie Dusetzina
02:20:00
This week we begin the episode by discussing MONALEESA-7 and why ribociclib has been shown to increase overall survival while palbociclib has not. We finish the episode with an in-depth interview with Dr. Stacie Dusetzina of Vanderbilt University on her work in pharmacoeconomics, specifically we discuss her work on the market value of cancer drugs. MONALEESA-7: doi.org/10.1056/NEJMoa1903765 Free drug samples are a marketing tool: doi.org/10.2105/AJPH.2007.114249 Back us on Patreon! www.patreon.com/plenarysession
Jun 27, 2019
1.66 Employing Medical Writers & Frequentist vs Bayesian Methods with Dr. Allen Pannell
01:03:58
This week we open with a critical take on our current system of disseminating scientific research, specifically focusing on the prevalence of -- and dependence on -- medical writers. In the second half of the episode, we interview Dr. Allen Pannell of the Haslam College of Business at the University of Tennessee on using a Frequentist approach vs a Bayesian approach in the context of a single clinical trial. Frequentist vs Bayesian: doi.org/10.1136/bmjopen-2018-024256 Dr. Pannell's breast cancer support group: https://www.breastconnect.org/ Dr. Pannell's research project: http://tinyurl.com/peerErPrHer2 Back us on Patreon! www.patreon.com/plenarysession
Jun 20, 2019
1.65 BONUS! Focusing and Building Your Presence on Twitter
00:39:58
In this BONUS episode we give advice on how to use Twitter effectively: how to focus your content, how to build your Twitter following, and how to conceptualize of the platform as an information network. Back us on Patreon! www.patreon.com/plenarysession
Jun 12, 2019
1.64 Effectiveness of Cancer Screening with Dr. Joaquín Chapa and POLO with Dr. Emerson Chen
01:07:35
This week we discuss the recent paper "Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?" with its author, Dr. Joaquín Chapa of OHSU. We then revisit the POLO trial with Dr. Emerson Chen of OHSU, who disagrees with last episode's analysis. Effectiveness of Screening: doi.org/10.1016/j.mayocp.2019.02.016 POLO: doi.org/10.1056/NEJMoa1903387 Back us on Patreon! www.patreon.com/plenarysession
Jun 06, 2019
1.63 POLO, TITAN, & from ASCO: FDA Approval, Surrogate Endpoints, and Patient Experience
01:23:16
This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO. POLO: doi.org/10.1056/NEJMoa1903387 TITAN: doi.org/10.1056/NEJMoa1903307 Back us on Patreon! www.patreon.com/plenarysession
Jun 04, 2019
1.62 Rates of Cancer Screening, BILCAP Outcry, Waterfall Plots and Response Rate, & Dr. Jeff Sharman
01:31:32
We begin this episode by responding to listener feedback from episode 1.61's discussion of clinic appointment time and rates of cancer screening. We also tackle listeners' outcry over our take-down of BILCAP (spoiler alert: BILCAP is still a null trial) and how outcry like this highlights the need to train clinicians to think probabilistically. From there, we move on to discussing the recent paper by Myung Sun Kim in JAMA Network Open on waterfall plots and how they are a visual distortion of response rate. We end the episode with an interview with Dr. Jeff Sharman of Willamette Valley Cancer Institute in Eugene, Oregon on community oncology, enrolling patients in clinical trials, expertise of academia, and using real-world evidence. Waterfall plots: doi.org/10.1001/jamanetworkopen.2019.3981 Back us on Patreon! www.patreon.com/plenarysession
May 23, 2019
1.61 Postpublication Metrics of RCTs, PCP Appointment Time, Bortezomib, & Dr. Christopher Booth
02:34:36
This week we cover three papers -- "Postpublication Metrics of Randomized Clinical Trials With and Without Null Findings" by Murray et al. in JAMA, "Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening" by Hsiang et al. in JAMA Network Open, and "Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers" by Drilon et al. in Molecular Case Studies. We end with an interview with Dr. Christopher Booth of Queens University in Kingston, Ontario, conducted in the Plenary Session Mobile Command Unit. Postpublication Metrics: doi.org/10.1001/jama.2019.2994 PCP Appointment Time: doi.org/10.1001/jamanetworkopen.2019.3403 Exceptional Responders: doi.org/10.1101/mcs.a003665 Back us on Patreon! www.patreon.com/plenarysession
May 15, 2019
1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung
01:20:08
We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs. Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053 Back us on Patreon! www.patreon.com/plenarysession
May 09, 2019
1.59 BONUS! Should Evidence Come with an Expiration Date? with Palmer Greene
00:18:56
In this BONUS episode, we interview Palmer Greene, a fourth-year medical student at the University of Chicago Pritzker School of Medicine, on his recent paper: "Should Evidence Come with an Expiration Date?", published in the Journal of General Internal Medicine. Expiration Date?: doi.org/10.1007/s11606-019-05032-4 Back us on Patreon! www.patreon.com/plenarysession
May 08, 2019
1.58 Magic Mouthwash with Dr. Arjun Gupta & Precision Oncology with Dr. Talal Hilal
01:34:08
This week we discuss three paired papers on precision oncology published in Nature Medicine and then, later in the episode, go in-depth on the implications of these negative studies with Dr. Talal Hilal of the Mayo Clinic. We also discuss the use of magic mouthwash for oral mucositis with Plenary Session fan, Dr. Arjun Gupta of Johns Hopkins University. WINTHER: doi.org/10.1038/s41591-019-0424-4 TARGET: doi.org/10.1038/s41591-019-0380-z I-PREDICT: doi.org/10.1038/s41591-019-0407-5 Magic mouthwash: doi.org/10.1001/jamainternmed.2018.6223 Back us on Patreon! www.patreon.com/plenarysession
May 07, 2019
1.57 BONUS! Control Arm Quality in RCTs Leading to Anticancer Drug FDA Approval with Dr. Talal Hilal
00:33:33
In this BONUS episode, we interview Dr. Talal Hilal of the Mayo Clinic on his paper that was published today in JAMA Oncology, titled "Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration". Control Arm Quality: doi.org/10.1001/jamaoncol.2019.0167 Back us on Patreon! www.patreon.com/plenarysession
May 02, 2019
1.56 BONUS! Real World Data & the Search for Meaningful Cancer Care with Dr. Christopher Booth
00:48:42
This BONUS episode is the recording of a Grand Rounds lecture that Dr. Christopher Booth of Queen's University in Kingston, Canada gave this morning (May 1, 2019) at OHSU. The title is "Achieving the Achievable: Real World Data and the Search for Meaningful Cancer Care". Back us on Patreon! www.patreon.com/plenarysession
May 01, 2019
1.55 Role of a Professional Society & More with Dr. Cliff Hudis of ASCO
01:39:37
This week we sit down with Dr. Cliff Hudis, the CEO of the American Society of Clinical Oncology, to discuss the role of a professional society, the evolution of oncology, building a career, and more. Back us on Patreon! www.patreon.com/plenarysession
Apr 29, 2019
1.54 Association of Patient Characteristics and Tumor Genomics with Clinical Outcomes & SABR-COMET
00:33:53
In this week's episode, we break down two recently published papers. The first is "Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database" by Singal et al., published in JAMA. The second is "Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial" by Palma et al., published in The Lancet. Characteristics and genomics: doi.org/10.1001/jama.2019.3241 SABR-COMET: doi.org/10.1016/S0140-6736(18)32487-5 Back us on Patreon! www.patreon.com/plenarysession
Apr 18, 2019
1.53 CALGB 50303, REMoDL-B, & REMS, Orphan Drug Act, and Role of the FDA with Dr. Ameet Sarpatwari
01:46:28
We begin this episode with a discussion of two recent clinical trials in lymphoma: CALGB 50303 and REMoDL-B, respectively published in the Journal of Clinical Oncology and The Lancet Oncology. We include a primer on the history of lymphoma and the development of R-CHOP. We follow that with an in-depth interview with Dr. Ameet Sarpatwari of the Harvard Medical School on Risk Evaluation and Mitigation Strategies (REMS), the Orphan Drug Act, and, broadly, the purpose of the US FDA. CALGB 50303: doi.org/10.1200/JCO.18.01994 REMoDL-B: doi.org/10.1016/S1470-2045(18)30935-5 Dr. Sarpatwari's online course: https://www.edx.org/course/the-fda-and-prescription-drugs-current-controversies-in-context Back us on Patreon! www.patreon.com/plenarysession
Apr 11, 2019
1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson
00:59:37
In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X Rivaroxaban: doi.org/10.1056/NEJMoa1814630 Apixaban: doi.org/10.1056/NEJMoa1814468 Back us on Patreon! www.patreon.com/plenarysession
Apr 04, 2019
1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen
00:25:47
In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months. Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351 Back us on Patreon! www.patreon.com/plenarysession
Apr 02, 2019
1.50 Replacing RCTs, Physicians on Twitter, Open-Access, & Orthopedics with Dr. Kathryn Schabel
01:56:21
This week we tackle the recent paper published in the Journal of Clinical Oncology titled "Comparison of Population-Based Observational Studies With Randomized Trials in Oncology" as well as a couple papers lamenting physicians' use of Twitter and the open-access model for journal publishing. We end the episode with an in-depth interview with Dr. Kathryn Schabel of OHSU on orthopedic surgery and how she practices. Observational Studies vs RCTs: doi.org/10.1200/JCO.18.01074 Back us on Patreon! www.patreon.com/plenarysession
Mar 29, 2019
1.49 Student Questions, Boeing 737 Max, Pancreatic Surveillance, Leukemia Drugs with Dr. Elihu Estey
01:54:57
We begin this episode by answering questions from a med student who is a Plenary Session fan. We transition from there to a discussion of the recent news stories on the FAA's handling of the Boeing 737 Max controversy and how this reflects on other USA regulatory agencies like the FDA. After a critique of the recent paper "Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance" published in the Journal of Clinical Oncology, we end with an interview with Dr. Elihu Estey of the University of Washington on his 40 years of experience as an oncologist, the "Renaissance" of drugs for leukemia, and advice for trainees on how to approach career goals. Pancreatic Surveillance: doi.org/10.1200/JCO.18.01512 Back us on Patreon! www.patreon.com/plenarysession
Mar 22, 2019
1.48 Falsified Data in Meta-Analyses and the Expert Halo Effect with Dr. Stephanie Halvorson
01:00:17
This week we dive deep into an article in JAMA IM on falsified data in meta-analyses. We also discuss the recent JAMA viewpoint "Reducing the Expert Halo Effect on Pharmacy and Therapeutics Committees" with its author, Dr. Stephanie Halvorson of OHSU. Falsified data: doi.org/10.1001/jamainternmed.2014.7774 Expert Halo Effect: doi.org/10.1001/jama.2018.20789 Back us on Patreon! www.patreon.com/plenarysession
Mar 13, 2019
1.47 BONUS! Medical Reversal: Class Lecture
00:56:40
This BONUS episode is a lecture on medical reversal that was pre-recorded for a class at Harvard Medical School. The recording was played for students in February of 2019 and followed by a Q&A. The slides referenced are available to Patreon supporters. Back us on Patreon! www.patreon.com/plenarysession
Mar 11, 2019
1.46 BONUS! Personal Finances with Dr. Tom Beer
01:16:42
In this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing. Back us on Patreon! www.patreon.com/plenarysession
Mar 08, 2019
1.45 Real-World Data, Gottlieb, & Using the EHR for Meaningful Improvement with Dr. Deborah Cohen
00:59:03
This week's episode begins with praise for the recent article by Booth CM, Karim S, and Mackillop WJ on real-world data published in Nature Reviews Clinical Oncology. Next, we tackle the resignation of Scott Gottlieb as FDA commissioner and how we can measure the success of the FDA. Finally, we have an interview with Dr. Deborah Cohen of OHSU on effective communication between the clinician and the patient and how we can use data from the Electronic Health Record to make meaningful improvements in care. Real-world data: doi.org/10.1038/s41571-019-0167-7 Back us on Patreon! www.patreon.com/plenarysession
Mar 06, 2019
1.44 BONUS! Screen Time and Children's Performance
00:46:54
This BONUS episode is the recording of a lecture given as part of the medical school class Appraising Medical Literature, taught at OHSU. This clip from the class critiques the recent JAMA Pediatrics paper "Association Between Screen Time and Children’s Performance on a Developmental Screening Test". Screen Time: doi.org/10.1001/jamapediatrics.2018.5056 Back us on Patreon! www.patreon.com/plenarysession
Mar 01, 2019
1.43 Andexanet Alfa with Dr. Tom Deloughery & National Medicaid Policy with Dr. John McConnell
01:41:56
In this episode we discuss the controversy over the recent article in NEJM, "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors", with Dr. Tom Deloughery of OHSU. We end with an interview with Dr. John McConnell, also of OHSU, on health economics and Medicaid. Andexanet Alfa: doi.org/10.1056/NEJMoa1814051 Back us on Patreon! www.patreon.com/plenarysession
Feb 22, 2019
1.42 Caplacizumab for TTP with Dr. Sven Olson & Economics of Drug Pricing with Dr. Inma Hernández
01:16:45
In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices. Caplacizumab: doi.org/10.1056/NEJMoa1806311 Back us on Patreon! www.patreon.com/plenarysession
Feb 13, 2019
1.41 Geneva Oath and Financial Relationships Among Guideline Authors with Dr. Joshua Niforatos
00:57:14
We feature two interviews this week: the first is a hallway conversation with [soon-to-be] Dr. Antonious Hazim of OHSU on the Declaration of Geneva and the second is a discussion with [soon-to-be] Dr. Joshua Niforatos on his recent paper in The American Journal of Emergency Medicine, titled "Financial relationships with industry among guideline authors for the management of acute ischemic stroke". Financial relationships: doi.org/10.1016/j.ajem.2019.01.037 Back us on Patreon! www.patreon.com/plenarysession
Feb 09, 2019
1.40 The World of Hematology with Dr. Thomas Deloughery
01:05:01
This episode features an interview with hematologist Dr. Thomas Deloughery of OHSU. We cover a broad range of topics including 23andMe, wilderness medicine, academia, and Twitter. We'll be back next week with our regular introductory monologue! Back us on Patreon! www.patreon.com/plenarysession
Feb 06, 2019
1.39 Looking Back On a Tenure in Medicine with Dr. Alex Denes
01:04:12
In this episode we interview Dr. Alex Denes of OHSU on his decades-long career in medicine: what practices have changed and what have stayed the same. No monologue this week - we'll be back next week with more insights! Back us on Patreon! www.patreon.com/plenarysession
Feb 02, 2019
1.38 Lartruvo, New Directions for Cancer Trials, Gene Expression Profiling, & Dr. Miriam Knoll
01:37:45
In this episode we tackle Eli Lilly's drug Lartruvo (olaratumab) and the under-powered phase II trial that led to its FDA accelerated approval; a viewpoint in JAMA on new directions for cancer trials; and gene expression profiling for carcinoma of unknown primary. We end with an interview with Dr. Miriam Knoll of Hackensack Meridian Health on employment after residency or fellowship, residency training, and the medical specialty pipeline. Back us on Patreon! www.patreon.com/plenarysession
Jan 26, 2019
1.37 BONUS! Medical Reversal for a General Audience
00:43:33
This BONUS episode is the recording of a talk given at the Salem City Club on January 11, 2019. It's the talk on medical reversal that has been featured in previous episodes, but this time the format and content have been updated for a broader, more general audience. Back us on Patreon! www.patreon.com/plenarysession
Jan 18, 2019
1.36 Generic Price Competition & Military Surgical Advances with Dr. Martin Schreiber
01:16:18
This week we dive into the recent paper by Drs. Cole and Dusetzina titled "Generic Price Competition For Specialty Drugs: Too Little, Too Late?". We also have an interview with Dr. Martin Schreiber of OHSU on his experiences as a trauma surgeon, both stateside and on the battlefield. Generic Price Competition: https://doi.org/10.1377/hlthaff.2017.1684 Back us on Patreon! www.patreon.com/plenarysession
Jan 15, 2019
1.35 BONUS! Conflict of Interest in Oncology
00:45:51
This BONUS episode is the recording of a lecture given to the Bioethics Study Group at OHSU on January 9, 2019 on conflict of interest, specifically in the field of oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession
Jan 10, 2019
1.34 Endpoints in ECOG-ACRIN 2511, Update to KEYNOTE-024, & Mentorship with Dr. Joseph Shatzel
01:10:47
In this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival and crossover results to KEYNOTE-024. We end with an interview with Dr. Joseph Shatzel of OHSU on mentorship. ECOG-ACRIN 2511: http://doi.org/10.1200/JCO.18.00264 KEYNOTE-024 update: http://doi.org/10.1200/JCO.18.00149 Back us on Patreon! www.patreon.com/plenarysession
Jan 10, 2019
1.33 Guarantee-Time Bias & Trials, Philanthropy, and Cancer Research with Dr. Tom Beer
01:32:12
In this episode we discuss guarantee-time bias in the context of the recent JAMA Oncology paper titled "Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer". We also have an interview with Dr. Tom Beer, the Deputy Director of the OHSU Knight Cancer Institute, on clinical trials, leadership, philanthropy, and future directions in cancer research. Profiling preexisting antibodies: doi.org/10.1001/jamaoncol.2018.5860 Back us on Patreon! www.patreon.com/plenarysession
Jan 05, 2019
1.32.1 Radiation Oncology with Dr. Brian Kavanagh
01:11:04
Episode 1.32 ran a little long, so this is episode 1.32.1 - we broke out the interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado, to make the interview more accessible. Back us on Patreon! www.patreon.com/plenarysession
Jan 04, 2019
1.32 Rating Metrics, Conflict of Interest in the News, & Radiation Oncology with Dr. Brian Kavanagh
01:59:35
This week we discuss various academic indices including the h-index and the new Altmetric score, and we go over the recent NY Times article on conflict of interest. We end with an interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado. NY Times: https://www.nytimes.com/2018/12/31/upshot/congratulations-on-the-promotion-but-did-science-get-a-demotion.html Back us on Patreon! patreon.com/plenarysession
Jan 03, 2019
1.31 Ketogenic Diet, COMET-1 and COMET-2, the Health Insurance Marketplace with Dr. Jane Zhu
01:35:03
We begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, two failed randomized controlled trials of cabozantinib versus prednisone or mitoxantrone-prednisone in metastatic castration-resistant prostate cancer. We end with an interview on instabilities in the health insurance marketplace with Dr. Jane Zhu of OHSU, an expert in the Affordable Care Act. Keto diet + PI3 kinase: https://www.nytimes.com/2018/12/05/magazine/its-time-to-study-whether-eating-particular-diets-can-help-heal-us.html COMET-1: http://doi.org/10.1200/jco.2015.65.5597 COMET-2: https://doi.org/10.1016/j.eururo.2018.11.033 Back us on Patreon! https://www.patreon.com/plenarysession
Dec 27, 2018
1.30 BONUS! Clinical Trial Endpoints, Drug Approval, Incentives in Oncology
01:10:06
This BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession
Dec 19, 2018
1.29 RCT of Parachutes and Frameworks for Internal Medicine with Dr. Andre Mansoor
01:17:47
We begin this episode with a critique of the recent paper in the BMJ, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial" and we end it with an interview with Dr. Andre Mansoor, discussing his new book: "Frameworks for Internal Medicine." Parachutes: https://www.bmj.com/content/363/bmj.k5094 Back us on Patreon! https://www.patreon.com/plenarysession
Dec 18, 2018
1.28 Questionable FDA Drug Approvals and Building a Career with Dr. Chadi Nabhan
01:04:45
In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of the American Society of Hematology in San Diego.
Dec 13, 2018
1.27 BONUS! Medical Reversal
00:57:46
This BONUS episode is the recording of a lecture given to hospitalists at Kaiser Permanente on November 14, 2018. It's a slightly different version of the talk on medical reversals that we recorded for episode 1.16. Backers of our Patreon will be sent accompanying slides. Back us on Patreon: https://www.patreon.com/plenarysession
Dec 06, 2018
1.26 Lesson From an ASH Abstract, Behind the Scenes of a Residency Program with Dr. Sima Desai
01:14:10
Having just returned from the 2018 American Society of Hematology (ASH) Annual Meeting, we begin this episode by discussing the abstract of a study that stretches its conclusions. We dedicate most of the episode to an interview with Dr. Sima Desai, the program director for OHSU's Internal Medicine Residency Program. She gives some great insight on the program's inner workings. ASH abstract: https://ash.confex.com/ash/2018/webprogram/Paper117448.html We have also launched our Patreon page! Become a patron at www.patreon.com/plenarysession.
Dec 04, 2018
1.25 Welch's Legacy, Interpreting NGS, Uncertainty over Pregabalin, Beyond EBM with Dr. Sam Edwards
01:20:41
In this episode we discuss: Dr. Gilbert Welch's Wikipedia page and how we should keep his decades of work in perspective, a Twitter conversation between experts on differing interpretations of results from next-generation sequencing, the new paper in JAMA titled "Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications", and finally, along with Dr. Sam Edwards of OHSU, we criticize the recent perspective piece in NEJM titled "Beyond Evidence-Based Medicine". Welch's Wikipedia: https://en.wikipedia.org/wiki/H._Gilbert_Welch Pregabalin: doi.org/10.1001/jamainternmed.2018.5705 Beyond EBM: doi.org/10.1056/NEJMp1806984 We have also launched our Patreon page! Become a patron at https://www.patreon.com/plenarysession.
Nov 27, 2018
1.24 Useless Medical Conferences and Dr. Adam Obley on Vascepa, Fish Oil, Vitamin D and Methotrexate
00:50:18
In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate. Medical conferences: doi.org/10.1001/jama.2012.360
Nov 20, 2018
1.23 BONUS! Developing Technology with Fewer Reversals: Maybe We Need More Translation Failure
01:00:10
This BONUS episode is the recording of a lecture given as part of the Biomedical Engineering Seminar series at Oregon Health & Science University on November 9, 2018. The talk is on how to move technological devices to the clinic with fewer reversals.
Nov 15, 2018
1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner
01:16:00
In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency. Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762 Immunotherapy combinations: http://doi.org/10.1056/NEJMp1803602 9 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6 Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779
Nov 13, 2018
1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees
01:12:41
In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees. Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277 Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527 Reporting harms: doi.org/10.1136/bmj.k4383
Nov 06, 2018
1.20 Precision Oncology: Some Benefit, Mostly Hype and Mentorship with Dr. Andrae Vandross
01:36:58
We begin this episode analyzing the unrepentant hype of precision oncology in a monologue that was originally one half of a debate titled: "Is Precision Oncology Generating Patient Benefit or Just Hype?" We conclude with an interview with Dr. Andrae Vandross on the mentor/mentee relationship.
Oct 30, 2018
1.19 BONUS! Introduction to Cancer Drug Policy
00:49:39
This BONUS episode is the recording of a lecture given as part of a Cancer Intersession course for med students at Oregon Health & Science University on October 25, 2018. The talk is an introduction to cancer drug policy.
Oct 26, 2018
1.18 IMpassion130 and Hot-Spotting with Dr. Brian Chan
01:02:31
In this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running that tests whether Dr. Gawande's idea of "hot-spotting" -- tailoring interventions to medically complex patients -- does decrease hospitalizations. IMpassion130: doi.org/10.1056/NEJMoa1809615 Hot-spotting: https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters
Oct 23, 2018
1.17 BONUS! Interpretation of Cancer Clinical Trials
01:18:03
This BONUS episode is the recording of a two-part talk addressed to oncology fellows given at Oregon Health & Science University on October 5 and October 12, 2018. The talk is on how to interpret cancer clinical trials.
Oct 22, 2018
1.16 BONUS! Crowdsourcing Data Analysis and Medical Reversal: Why 40% of What We Do is Wrong
00:55:50
This BONUS episode is the recording of the Hospitalist Grand Rounds given at Oregon Health & Science University on October 11, 2018. The talk is on medical reversal. Before the talk we discuss the paper "Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results" by Silberzahn et al., published in Advances in Methods and Practices in Psychological Science. Paper: doi.org/10.1177/2515245917747646
Oct 17, 2018
1.15 Minimally Effective Treatments, CheckMate 331, and Dr. Adam Obley on Low-Value Healthcare
01:18:22
In this episode we review the recent paper in Nature Reviews Clinical Oncology by Booth, C.M. and Detsky, A.S. titled "Why patients receive treatments that are minimally effective?". We discuss the failure of CheckMate 331 to meet its primary endpoint despite having received accelerated FDA approval. Finally, we bring back Dr. Adam Obley (from episode 1.01) to talk about low-value healthcare, medical education, social media, and more!
Oct 16, 2018
1.14 BONUS! Immunotherapy in Desperation and the Pennington Lecture: Myths of Medicine and Marketing
00:56:32
This BONUS episode is the recording of the 22nd annual Pennington Lecture given at Oregon Health & Science University on September 21, 2018. The lecture is on seven myths of medicine and marketing. Before the lecture we read and discuss the editorial "Desperation Oncology" by Tito Fojo, published in Seminars in Oncology.
Oct 12, 2018
1.13 KEYNOTE-189, Dr. Talal Hilal on MRD, and Medical Education with Dr. Adam Cifu
01:37:06
Listen in for a breakdown of the good and the bad of KEYNOTE-189(trial published in NEJM), a discussion with Dr. Talal Hilal of the Mayo Clinic on the rise of minimal residual disease as a clinical endpoint, and an interview with Dr. Adam Cifu of the University of Chicago Pritzker School of Medicine on medical education, sham trials, and more.
Oct 08, 2018
1.12 BONUS! Evidence-Based Medicine Has Been Hijacked in Oncology
00:37:00
This BONUS episode is the recording of a Grand Rounds talk given at Oregon Health & Science University on September 19, 2018. The talk was inspired by the article by JPA Ioannidis titled "Evidence-based medicine has been hijacked: a report to David Sackett", published May 2016 in the Journal of Clinical Epidemiology.
Oct 03, 2018
1.11 Peanut Gallery, Research Parasites, Appendectomies, HRQoL and PFS, Dr. Bishal Gyawali
01:48:39
We discuss Dr. Califf's comment on the "social media peanut gallery of experts", Dr. Drazen's comment on "research parasites" and his retirement from NEJM, the recent paper in JAMA on long-term follow up for antibiotics as compared to appendectomies, and the paper in JAMA Internal Medicine on the relationship between health-related quality of life and progression-free survival. Finally, we interview Dr. Bishal Gyawali on a variety of topics, including cancer groundshot.
Oct 02, 2018
1.10 Criticism via Twitter, PACIFIC, PCI for CAD, and Dr. Rebecca Cooney of The Lancet
01:12:40
Today we tackle some cardiologists' opposition to criticizing clinical trials on Twitter, the PACIFIC trial on durvalumab in stage III non–small-cell lung cancer, and the recent paper in Heart: "Percutaneous Coronary Intervention for Stable Coronary Artery Disease" by R.K. Al-Lamee, A.N. Nowbar, and D.P. Francis. We end with an interview on academic medical publishing with Dr. Rebecca Cooney, North American Executive Editor of The Lancet.
Sep 25, 2018
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
00:33:41
Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.
Sep 20, 2018
1.08 Hyperprolific authors, NCCN with Jeff Wagner, and Dr. Renee Dversdal on Ultrasounds
01:02:32
In this episode we discuss hyperprolific authors and the recent comment in Nature by JPA Ioannidis, R Klavans, & KW Boyack; NCCN guidelines with fourth-year medical student Jeffrey Wagner; and point-of-care ultrasounds with Dr. Renee Dversdal of OHSU.
Sep 14, 2018
1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola
01:02:43
In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.
Sep 11, 2018
1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority
01:22:04
In this episode we break down the RELEVANCE trial published in the New England Journal of Medicine; discuss big data in observational studies with Jenny Gill, MS; and interview Dr. Catherine Livingston of OHSU, an expert in healthcare policy, on her work with the Oregon Health Authority and state Medicaid.
Sep 07, 2018
1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity
01:00:56
In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.
Sep 05, 2018
1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser
00:56:53
This week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.
Aug 30, 2018
1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross
01:06:02
We're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA approval for nivolumab in small-cell lung cancer. In the second half of the show, we'll interview Dr. Andrae Vandross, a community oncologist at UCLA Medical Center.
Aug 21, 2018
1.02: HemOnc Fellowship and Hype in Cancer Medicine with Dr. Jeremy Cetnar
00:35:16
In episode 2, we discuss the fellowship program and then take a deep dive into hype surrounding cancer drugs. Our guest is Jeremy Cetnar, MD from Oregon Health & Science University.
Aug 16, 2018
1.01: Introduction and Dr. Adam Obley
00:47:25
Join us for an introduction to who we are and what our podcast is about, then stick around for a hard-hitting discussion of evidence-based medicine, randomized controlled trials, sham controls, and broad next-generation sequencing in cancer. Our guest is Adam Obley, an Assistant Professor of Medicine at Oregon Health & Science University.
Aug 14, 2018